PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.41%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-25.41%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
610.74%
Positive net income growth while GNPX is negative. John Neff might see a big relative performance advantage.
609.26%
EPS growth above 1.5x GNPX's 34.62%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
609.26%
Diluted EPS growth above 1.5x GNPX's 34.62%. David Dodd would see if there's a robust moat protecting these shareholder gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
320.27%
OCF growth above 1.5x GNPX's 7.14%. David Dodd would confirm a clear edge in underlying cash generation.
320.27%
FCF growth above 1.5x GNPX's 7.14%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
419.54%
10Y OCF/share CAGR above 1.5x GNPX's 91.62%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
419.54%
5Y OCF/share CAGR above 1.5x GNPX's 96.48%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
400.10%
3Y OCF/share CAGR above 1.5x GNPX's 96.26%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
706.07%
Net income/share CAGR above 1.5x GNPX's 99.56% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
706.07%
5Y net income/share CAGR above 1.5x GNPX's 96.58%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
315.93%
3Y net income/share CAGR above 1.5x GNPX's 96.48%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
-251.89%
Negative equity/share CAGR over 10 years while GNPX stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-251.89%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-24.04%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.74%
Positive BV/share change while GNPX is negative. John Neff sees a clear edge over a competitor losing equity.
-14.44%
We’re deleveraging while GNPX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
30.71%
SG&A growth well above GNPX's 52.68%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.